



General description

INN	Vinblastine
ATC codes	L01CA01
Medicine type	Chemical agent
EML status history	<p>First added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2015 (TRS 994) for Hodgkin lymphoma</p> <p>Added in 2015 (TRS 994) for Kaposi sarcoma of unspecified primary site</p> <p>Added in 2015 (TRS 994) for Germ cell tumour of testis</p> <p>Added in 2015 (TRS 994) for Other specified malignant neoplasms of the ovary</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2021 (TRS 1035) for Other specified gliomas of brain</p> <p>Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive</p> <p>Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative</p> <p>Added in 2023 (TRS 1049) for Langerhans cell histiocytosis</p>
Wikipedia	Vinblastine 
DrugBank	Vinblastine 

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
 Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis



